Jaguar Health reports positive preliminary open — label crofelemer study results in adult short bowel syndrome patients with intestinal failure
Jaguar Health highlighted preliminary findings already presented Oct. 13, 2026 at the ACG meeting from an open-label crofelemer study in adult SBS-IF. Early results showed some patients improved on treatment, with output worsening in several cases once therapy stopped. Safety profile looked favorable, with no significa